Capsida Biotherapeutics Unveils Next-Generation Gene Therapy Manufacturing

THOUSAND OAKS, Calif.: THOUSAND OAKS, Calif., July 22, 2021 /PRNewswire/ -- Capsida Biotherapeutics Inc., a fully integrated biotechnology company creating a new class of targeted adeno-associated virus (AAV) gene therapies for patients with debilitating and life-threatening genetic disorders, today announced the opening of its state-of-the-art manufacturing facility in Thousand Oaks....

Click to view original post